Literature DB >> 22089248

Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.

Shigefumi Okamoto1, Hironori Yoshii, Masaaki Matsuura, Asato Kojima, Toyokazu Ishikawa, Takami Akagi, Mitsuru Akashi, Michiaki Takahashi, Koichi Yamanishi, Yasuko Mori.   

Abstract

To maintain immunity against Japanese encephalitis virus (JEV), a formalin-inactivated Japanese encephalitis (JE) vaccine should be administered several times. The repeated vaccination is not helpful in the case of a sudden outbreak of JEV or when urgent travel to a high-JEV-risk region is required; however, there are few single-injection JE vaccine options. In the present study, we investigated the efficacy of a single dose of a new effective JE virus-like particle preparation containing the JE envelope protein (JE-VLP). Although single administration with JE-VLP protected less than 50% of mice against lethal JEV infection, adding poly(γ-glutamic acid) nanoparticles (γ-PGA-NPs) or aluminum adjuvant (alum) to JE-VLP significantly protected more than 90% of the mice. A single injection of JE-VLP with either γ-PGA-NPs or alum induced a significantly greater anti-JEV neutralizing antibody titer than JE-VLP alone. The enhanced titers were maintained for more than 6 months, resulting in long-lasting protection of 90% of the immunized mice. Although the vaccine design needs further modification to reach 100% protection, a single dose of JE-VLP with γ-PGA-NPs may be a useful step in developing a next-generation vaccine to stop a JE outbreak or to immunize travelers or military personnel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089248      PMCID: PMC3255961          DOI: 10.1128/CVI.05412-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

Review 1.  Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia.

Authors:  J S Mackenzie; C A Johansen; S A Ritchie; A F van den Hurk; R A Hall
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

2.  Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004.

Authors:  Tetsuo Nakayama; Kazumasa Onoda
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

3.  In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(gamma-glutamic acid).

Authors:  Takami Akagi; Mariko Higashi; Tatsuo Kaneko; Toshiyuki Kida; Mitsuru Akashi
Journal:  Macromol Biosci       Date:  2005-07-14       Impact factor: 4.979

4.  Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection.

Authors:  E Konishi; S Pincus; E Paoletti; R E Shope; T Burrage; P W Mason
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

5.  Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier.

Authors:  Takami Akagi; Tatsuo Kaneko; Toshiyuki Kida; Mitsuru Akashi
Journal:  J Control Release       Date:  2005-08-24       Impact factor: 9.776

7.  Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study.

Authors:  Heechoul Ohrr; J B Tandan; Young Mo Sohn; Sun Heang Shin; Durga Prasad Pradhan; Scott B Halstead
Journal:  Lancet       Date:  2005 Oct 15-21       Impact factor: 79.321

8.  Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine.

Authors:  Asato Kojima; Atsushi Yasuda; Hideki Asanuma; Toyokazu Ishikawa; Akihisa Takamizawa; Kotaro Yasui; Takeshi Kurata
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein.

Authors:  E Konishi; P W Mason
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains).

Authors:  E Ohtaki; T Matsuishi; Y Hirano; K Maekawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

View more
  10 in total

1.  Oral administration of poly-γ-glutamate ameliorates atopic dermatitis in Nc/Nga mice by suppressing Th2-biased immune response and production of IL-17A.

Authors:  Tae-Young Lee; Doo-Jin Kim; Ji-Na Won; Il-Han Lee; Moon-Hee Sung; Haryoung Poo
Journal:  J Invest Dermatol       Date:  2013-09-11       Impact factor: 8.551

Review 2.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

Review 3.  Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?

Authors:  Fatemeh Farjadian; Mohsen Moghoofei; Soroush Mirkiani; Amir Ghasemi; Navid Rabiee; Shima Hadifar; Ali Beyzavi; Mahdi Karimi; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

Review 4.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Micelle-Based Adjuvants for Subunit Vaccine Delivery.

Authors:  Thomas Trimaille; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2015-09-25

Review 6.  Bacterial-Derived Polymer Poly-y-Glutamic Acid (y-PGA)-Based Micro/Nanoparticles as a Delivery System for Antimicrobials and Other Biomedical Applications.

Authors:  Ibrahim R Khalil; Alan T H Burns; Iza Radecka; Marek Kowalczuk; Tamara Khalaf; Grazyna Adamus; Brian Johnston; Martin P Khechara
Journal:  Int J Mol Sci       Date:  2017-02-02       Impact factor: 5.923

Review 7.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Authors:  Jesús Zepeda-Cervantes; Josué Orlando Ramírez-Jarquín; Luis Vaca
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

Review 8.  Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead.

Authors:  Gabriel Augusto Pires de Souza; Raíssa Prado Rocha; Ricardo Lemes Gonçalves; Cyntia Silva Ferreira; Breno de Mello Silva; Renato Fróes Goulart de Castro; João Francisco Vitório Rodrigues; João Carlos Vilela Vieira Júnior; Luiz Cosme Cotta Malaquias; Jônatas Santos Abrahão; Luiz Felipe Leomil Coelho
Journal:  Pathogens       Date:  2021-01-05

9.  Nanoparticles and nanoformulated drugs as promising delivery system in treatment of microbial-induced CNS infection: a systematic review of literature.

Authors:  Ali Lashkari; Reza Ranjbar
Journal:  J Neurovirol       Date:  2021-07-05       Impact factor: 2.643

10.  Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice.

Authors:  Yu-Hsiu Chang; Der-Jiang Chiao; Yu-Lin Hsu; Chang-Chi Lin; Hsueh-Ling Wu; Pei-Yun Shu; Shu-Fen Chang; Jui-Huan Chang; Szu-Cheng Kuo
Journal:  Viruses       Date:  2020-03-19       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.